Augmented neutralisation resistance of emerging omicron subvariants BA.2.12.1, BA.4, and BA.5

doi:10.1016/S1473-3099(22)00422-4

Comment

. 2022 Aug;22(8):1117-1118.

doi: 10.1016/S1473-3099(22)00422-4. Epub 2022 Jun 28.

Augmented neutralisation resistance of emerging omicron subvariants BA.2.12.1, BA.4, and BA.5

Affiliations

¹ Infection Biology Unit, German Primate Center, 37077 Göttingen, Germany; Faculty of Biology and Psychology, Georg-August-University Göttingen, Göttingen, Germany.
² Division of Molecular Immunology, Department of Internal Medicine 3, Friedrich-Alexander University of Erlangen-Nürnberg, Erlangen, Germany.
³ Department for Rheumatology and Immunology, Hannover Medical School, Hannover, Germany.
⁴ Department for Rheumatology and Immunology, Hannover Medical School, Hannover, Germany; German Centre for Infection Research, partner site Hannover-Braunschweig, Hannover, Germany.
⁵ Infection Biology Unit, German Primate Center, 37077 Göttingen, Germany; Faculty of Biology and Psychology, Georg-August-University Göttingen, Göttingen, Germany. Electronic address: mhoffmann@dpz.eu.

PMID: 35777385
PMCID: PMC9239574
DOI: 10.1016/S1473-3099(22)00422-4

Comment

Augmented neutralisation resistance of emerging omicron subvariants BA.2.12.1, BA.4, and BA.5

Prerna Arora et al. Lancet Infect Dis. 2022 Aug.

. 2022 Aug;22(8):1117-1118.

doi: 10.1016/S1473-3099(22)00422-4. Epub 2022 Jun 28.

Authors

Affiliations

¹ Infection Biology Unit, German Primate Center, 37077 Göttingen, Germany; Faculty of Biology and Psychology, Georg-August-University Göttingen, Göttingen, Germany.
² Division of Molecular Immunology, Department of Internal Medicine 3, Friedrich-Alexander University of Erlangen-Nürnberg, Erlangen, Germany.
³ Department for Rheumatology and Immunology, Hannover Medical School, Hannover, Germany.
⁴ Department for Rheumatology and Immunology, Hannover Medical School, Hannover, Germany; German Centre for Infection Research, partner site Hannover-Braunschweig, Hannover, Germany.
⁵ Infection Biology Unit, German Primate Center, 37077 Göttingen, Germany; Faculty of Biology and Psychology, Georg-August-University Göttingen, Göttingen, Germany. Electronic address: mhoffmann@dpz.eu.

PMID: 35777385
PMCID: PMC9239574
DOI: 10.1016/S1473-3099(22)00422-4

No abstract available

PubMed Disclaimer

Conflict of interest statement

AK, IN, SP, and MH conduct contract research (ie, testing of vaccinee sera for neutralising activity against SARS-CoV-2) for an industrial entity, unrelated to this Correspondence. GMNB served as an adviser for Moderna, unrelated to this Correspondence. All other authors declare no competing interests. SP acknowledges funding by Bundesministerium für Bildung und Forschung (01KI2006D, 01KI20328A, 01KX2021), the Ministry for Science and Culture of Lower Saxony (14–76103–184, MWK HZI COVID-19), and the German Research Foundation (PO 716/11–1, PO 716/14–1). H-MJ received funding from BMBF (01KI2043, NaFoUniMedCovid19-COVIM: 01KX2021), Bavarian State Ministry for Science and the Arts, and Deutsche Forschungsgemeinschaft through the research training groups RTG1660 and TRR130, the Bayerische Forschungsstiftung (Project CORAd), and the Kastner Foundation. GMNB acknowledges funding by German Center for Infection Research (grant no 80018019238) and a European Regional Development Fund (Defeat Corona, ZW7–8515131).

Comment on

Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies.
Yamasoba D, Kosugi Y, Kimura I, Fujita S, Uriu K, Ito J, Sato K; Genotype to Phenotype Japan (G2P-Japan) Consortium. Yamasoba D, et al. Lancet Infect Dis. 2022 Jul;22(7):942-943. doi: 10.1016/S1473-3099(22)00365-6. Epub 2022 Jun 9. Lancet Infect Dis. 2022. PMID: 35690075 Free PMC article. No abstract available.
BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection.
Cao Y, Yisimayi A, Jian F, Song W, Xiao T, Wang L, Du S, Wang J, Li Q, Chen X, Yu Y, Wang P, Zhang Z, Liu P, An R, Hao X, Wang Y, Wang J, Feng R, Sun H, Zhao L, Zhang W, Zhao D, Zheng J, Yu L, Li C, Zhang N, Wang R, Niu X, Yang S, Song X, Chai Y, Hu Y, Shi Y, Zheng L, Li Z, Gu Q, Shao F, Huang W, Jin R, Shen Z, Wang Y, Wang X, Xiao J, Xie XS. Cao Y, et al. Nature. 2022 Aug;608(7923):593-602. doi: 10.1038/s41586-022-04980-y. Epub 2022 Jun 17. Nature. 2022. PMID: 35714668 Free PMC article.

Cited by

SARS-CoV-2 Omicron BA.5: Evolving tropism and evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern.
Aggarwal A, Akerman A, Milogiannakis V, Silva MR, Walker G, Stella AO, Kindinger A, Angelovich T, Waring E, Amatayakul-Chantler S, Roth N, Manni S, Hauser T, Barnes T, Condylios A, Yeang M, Wong M, Jean T, Foster CSP, Christ D, Hoppe AC, Munier ML, Darley D, Churchill M, Stark DJ, Matthews G, Rawlinson WD, Kelleher AD, Turville SG. Aggarwal A, et al. EBioMedicine. 2022 Oct;84:104270. doi: 10.1016/j.ebiom.2022.104270. Epub 2022 Sep 18. EBioMedicine. 2022. PMID: 36130476 Free PMC article.
Antibody-dependent cellular cytotoxicity against SARS-CoV-2 Omicron sub-lineages is reduced in convalescent sera regardless of infecting variant.
Richardson SI, Kgagudi P, Manamela NP, Kaldine H, Venter EM, Pillay T, Lambson BE, van der Mescht MA, Hermanus T, Balla SR, de Beer Z, de Villiers TR, Bodenstein A, van den Berg G, du Pisanie M, Burgers WA, Ntusi NAB, Abdullah F, Ueckermann V, Rossouw TM, Boswell MT, Moore PL. Richardson SI, et al. Cell Rep Med. 2023 Jan 17;4(1):100910. doi: 10.1016/j.xcrm.2022.100910. Epub 2022 Dec 22. Cell Rep Med. 2023. PMID: 36603577 Free PMC article.
Lessons Learnt from COVID-19: Computational Strategies for Facing Present and Future Pandemics.
Pavan M, Moro S. Pavan M, et al. Int J Mol Sci. 2023 Feb 23;24(5):4401. doi: 10.3390/ijms24054401. Int J Mol Sci. 2023. PMID: 36901832 Free PMC article. Review.
Spike mutations contributing to the altered entry preference of SARS-CoV-2 omicron BA.1 and BA.2.
Hu B, Chan JF, Liu H, Liu Y, Chai Y, Shi J, Shuai H, Hou Y, Huang X, Yuen TT, Yoon C, Zhu T, Zhang J, Li W, Zhang AJ, Zhou J, Yuan S, Zhang BZ, Yuen KY, Chu H. Hu B, et al. Emerg Microbes Infect. 2022 Dec;11(1):2275-2287. doi: 10.1080/22221751.2022.2117098. Emerg Microbes Infect. 2022. PMID: 36039901 Free PMC article.
Systematical assessment of the impact of single spike mutations of SARS-CoV-2 Omicron sub-variants on the neutralization capacity of post-vaccination sera.
Katzmarzyk M, Clesle DC, van den Heuvel J, Hoffmann M, Garritsen H, Pöhlmann S, Jacobsen H, Čičin-Šain L. Katzmarzyk M, et al. Front Immunol. 2023 Nov 10;14:1288794. doi: 10.3389/fimmu.2023.1288794. eCollection 2023. Front Immunol. 2023. PMID: 38022629 Free PMC article.

See all "Cited by" articles

References

1. Hoffmann M, Krüger N, Schulz S, et al. The omicron variant is highly resistant against antibody-mediated neutralization: implications for control of the COVID-19 pandemic. Cell. 2022;185:447–456. e11. - PMC - PubMed
1. Schmidt F, Weisblum Y, Muecksch F, et al. Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. J Exp Med. 2020;217 - PMC - PubMed
1. Cameroni E, Bowden JE, Rosen LE, et al. Broadly neutralizing antibodies overcome SARS-CoV-2 omicron antigenic shift. Nature. 2022;602:664–670. - PMC - PubMed
1. Cao Y, Yisimayi A, Jian F, et al. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by omicron infection (version 2) bioRxiv. 2022 doi: 10.1101/2022.04.30.489997. published online June 14. (preprint). - DOI - PMC - PubMed
1. Yamasoba D, Kosugi Y, Kimura I, et al. Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies. Lancet Infect Dis. 2022;22:942–943. - PMC - PubMed

Publication types

Actions
Actions

LinkOut - more resources

Full Text Sources

[1] Hoffmann M, Krüger N, Schulz S, et al. The omicron variant is highly resistant against antibody-mediated neutralization: implications for control of the COVID-19 pandemic. Cell. 2022;185:447–456. e11. - PMC - PubMed

[2] Hoffmann M, Krüger N, Schulz S, et al. The omicron variant is highly resistant against antibody-mediated neutralization: implications for control of the COVID-19 pandemic. Cell. 2022;185:447–456. e11. - PMC - PubMed

[3] Schmidt F, Weisblum Y, Muecksch F, et al. Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. J Exp Med. 2020;217 - PMC - PubMed

[4] Schmidt F, Weisblum Y, Muecksch F, et al. Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. J Exp Med. 2020;217 - PMC - PubMed

[5] Cameroni E, Bowden JE, Rosen LE, et al. Broadly neutralizing antibodies overcome SARS-CoV-2 omicron antigenic shift. Nature. 2022;602:664–670. - PMC - PubMed

[6] Cameroni E, Bowden JE, Rosen LE, et al. Broadly neutralizing antibodies overcome SARS-CoV-2 omicron antigenic shift. Nature. 2022;602:664–670. - PMC - PubMed

[7] Cao Y, Yisimayi A, Jian F, et al. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by omicron infection (version 2) bioRxiv. 2022 doi: 10.1101/2022.04.30.489997. published online June 14. (preprint). - DOI - PMC - PubMed

[8] Cao Y, Yisimayi A, Jian F, et al. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by omicron infection (version 2) bioRxiv. 2022 doi: 10.1101/2022.04.30.489997. published online June 14. (preprint). - DOI - PMC - PubMed

[9] Yamasoba D, Kosugi Y, Kimura I, et al. Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies. Lancet Infect Dis. 2022;22:942–943. - PMC - PubMed

[10] Yamasoba D, Kosugi Y, Kimura I, et al. Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies. Lancet Infect Dis. 2022;22:942–943. - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Augmented neutralisation resistance of emerging omicron subvariants BA.2.12.1, BA.4, and BA.5

Affiliations

Augmented neutralisation resistance of emerging omicron subvariants BA.2.12.1, BA.4, and BA.5

Authors

Affiliations

Conflict of interest statement

Comment on

Similar articles

Cited by

References

Publication types

LinkOut - more resources

Full Text Sources